In a move to help position the company to keep pace with a growing demand for the development of biologics, which currently represent nearly 50% of AstraZeneca’s (IW 1000/170) overall pipeline, the company announced plans to expand its biologics manufacturing center in Frederick, Md.
The more than $200 million project will increase production capacity. Biologics currently represents nearly 50% of AstraZeneca’s overall pipeline.
“The expansion of our Frederick facility will support the progression of drug candidates across our core therapeutic areas, ultimately aiding us in our efforts to make a meaningful difference in the lives of patients through scientific leadership and innovative new treatments,” said Andrew D. Skibo, regional vice president of biologics supply for AstraZeneca.
“Our global biologics research and development arm, MedImmune, has a robust pipeline of more than 120 biologics, including more than 30 in clinical development,” Skibo added.
AstraZeneca’s Frederick biologics manufacturing center is an FDA licensed, large-scale cell culture production facility. The expansion project, which is anticipated to begin in December and expected to be complete in mid-2017, will add approximately 40,000 additional square feet of manufacturing, laboratory and administrative space. The expansion is also expected to bring a total of 300 new jobs to the site.
AstraZeneca’s Frederick manufacturing center is the largest biologics manufacturing facility within the company’s global network and portfolio of assets, and a worldwide industry leader in cell culture manufacturing. The site currently produces a pediatric medication, as well as other investigational biologic products.
